Your browser doesn't support javascript.
loading
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Mileshkin, Linda R; Moore, Kathleen N; Barnes, Elizabeth H; Gebski, Val; Narayan, Kailash; King, Madeleine T; Bradshaw, Nathan; Lee, Yeh Chen; Diamante, Katrina; Fyles, Anthony W; Small, William; Gaffney, David K; Khaw, Pearly; Brooks, Susan; Thompson, J Spencer; Huh, Warner K; Mathews, Cara A; Buck, Martin; Suder, Aneta; Lad, Thomas E; Barani, Igor J; Holschneider, Christine H; Van Dyk, Sylvia; Quinn, Michael; Rischin, Danny; Monk, Bradley J; Stockler, Martin R.
Affiliation
  • Mileshkin LR; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia. Electronic address: linda.mileshkin@petermac.org.
  • Moore KN; Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA.
  • Barnes EH; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Gebski V; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Narayan K; Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
  • King MT; School of Psychology, University of Sydney, Sydney, NSW, Australia.
  • Bradshaw N; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Lee YC; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Diamante K; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Fyles AW; National Cancer Institute of Canada Clinical Trial Group, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Small W; Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernadin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
  • Gaffney DK; Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
  • Khaw P; Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
  • Brooks S; Department of Medical Oncology, Auckland City Hospital, Auckland, New Zealand.
  • Thompson JS; Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA.
  • Huh WK; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Mathews CA; Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI, USA.
  • Buck M; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Suder A; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Lad TE; Division of Hematology-Oncology, Cook County Hospital, Chicago, IL, USA.
  • Barani IJ; Department of Radiation Oncology, St Joseph's Hospital and Medical Centre, Phoenix, AZ, USA.
  • Holschneider CH; Division of Gynecologic Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
  • Van Dyk S; Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
  • Quinn M; Oncology Unit, Royal Women's Hospital and University of Melbourne, Melbourne, VIC, Australia.
  • Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
  • Monk BJ; Division of Gynecologic Oncology, HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA.
  • Stockler MR; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Lancet Oncol ; 24(5): 468-482, 2023 05.
Article de En | MEDLINE | ID: mdl-37080223
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du col de l'utérus / Cisplatine Type d'étude: Clinical_trials Limites: Female / Humans / Middle aged Langue: En Journal: Lancet Oncol Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du col de l'utérus / Cisplatine Type d'étude: Clinical_trials Limites: Female / Humans / Middle aged Langue: En Journal: Lancet Oncol Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article